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Background/Aims: Currently, there is no consensus on the necessity of repeated radioiodine therapy (RAI) in
patients who show iodine uptake in the thyroid bed on a diagnostic whole-body scan (DxWBS) despite
undetectable thyroglobulin (Tg) levels after remnant ablation. The present study investigated the clinical outcomes
of scan-positive, Tg-negative patients (WBS+Tg-) who did or did not receive additional RAI.
Methods: We retrospectively reviewed 389 differentiated thyroid carcinoma patients who underwent a total
thyroidectomy and received high-dose RAI from January 2003 through December 2005. The patients were
classified according to surveillance DxWBS findings and TSH-stimulated Tg levels 6 to 12 months after the initial
RAI.
Results: Forty-four of the 389 patients (11.3%) showed thyroid bed uptake on a DxWBS despite negative Tg
levels (WBS+Tg-). There was no difference in clinical and pathological parameters between WBS+Tg- and WBS-
Tg- patients, except for an increased frequency of thyroiditis in the WBS+Tg- group. Among the 44 WBS+Tg-
patients, 27 subjects were treated with additional RAI; 25 subjects showed no uptake in subsequent DxWBS.
Two patients were evaluated only by ultrasonography (US) and displayed no persistent/recurrent disease. The
other 17 patients received no further RAI; Eight patients and two patients showed no uptake and persistent
uptake, respectively, on subsequent DxWBS. Six patients presented negative subsequent US findings, and one
was lost to follow-up. Over the course of 53.2 ± 10.1 months, recurrence/persistence was suspicious in two
patients in the treatment group.
Conclusions: There were no remarkable differences in clinical outcomes between observation and treatment
groups of WBS+Tg- patients. Observation without repeated RAI may be an alternative management option for
WBS+Tg- patients. (Korean J Intern Med 2010;25:408-414)
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INTRODUCTION
The detection of papillary thyroid carcinoma (PTC) has
been increasing globally due to the widespread use of
sensitive diagnostic tools such as high-resolution
ultrasonography (US). In addition to measurements of
serum thyroglobulin (Tg), whole-body scans (WBS) with
radioiodine has been considered the main tool for
detecting persistent or recurrent disease during follow-up
of differentiated thyroid carcinoma (DTC). However,
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recent published guidelines, as well as several previous
reports, discourage the use of diagnostic WBS (DxWBS)
as a follow-up method, especially for low-risk patients
with DTC because of its low sensitivity and the lack of
additional information it provides as compared with Tg
measurements [1-5].
A few recent reports suggest that lesions detected only
by diagnostic or therapeutic WBS without detectable Tg
levels could be recurrent/persistent disease or a clinically
significant lesion. This information has shifted the focus
back on the importance of WBS [6,7]. On the other hand,
previous findings have considered thyroid bed uptake in
WBS after total thyroidectomy and remnant ablation to be
clinically insignificant and evidence of remnant ablation
failure without regard to persistence/recurrent lesions in
DTC [2].
The present study was performed to evaluate the clinical
characteristics, prognosis, and possible management plan
of patients with positive WBS who demonstrate thyroid
bed uptake despite undetectable Tg levels after high-dose
radioiodine therapy (RAI). 
METHODS
Patients
A retrospective review was conducted on 699 patients
who had undergone total thyroidectomy for DTC and
received RAI from January 2003 through December 2005
at our institution. Patients were excluded if they did not
have high-dose RAI, follow-up Tg measurements were not
performed on a regular basis, thyroid stimulating
hormone (TSH) levels were < 30 IU/L at the time of
radioiodine scan, or they were positive for anti-Tg
antibody (Ab) (> 70 IU/mL) with Tg levels < 1 ng/mL. A
total of 389 patients with DTC were included. 
Radioiodine whole-body scan and remnant ablation
Thyroid hormone (T4) was withdrawn and replaced
with 25 µg of triiodothyronine (T3) every 12 hours for 2
weeks, and T3 was stopped for at least 2 weeks to
stimulate TSH > 30 IU/L, according to the institutional
protocols. The initial treatment dose was determined by
diagnostic 
123I-WBS performed prior to high-dose RAI and
post-operative histologic findings. The patients followed a
low-iodine diet for at least 2 weeks before the diagnostic
123I-WBS. After oral administration of approximately 111
MBq (3 mCi) of 
123I, scans were obtained using a high-
resolution collimator set at 159 keV with a 15% energy
window using the E-CAM dual detector system (Siemens,
Erlangen, Germany). In general, 3700 MBq (100 mCi)
was administered for patients with uptake limited to the
thyroid bed, 5500 MBq (150 mCi) when uptake was
suspected in the cervical region, and 7400 MBq (200 mCi)
for suspicious distant metastasis. All patients received
TSH-suppressive doses of L-thyroxine for at least 2 years.
Tg, anti-Tg antibody, anti-TPO antibody, and TSH
measurement
Serum Tg levels were measured using an immun-
oradiometric assay (IRMA) kit (CIS Bio International,
Cedex, France). The intra-assay coefficient of variation
(CV) was 7.7%, 2.6%, and 1.4% at 1.22, 43.8, and 116.0
ng/mL, respectively. The inter-assay CV was 16.7%, 3.1%,
and 2.0% at 0.8, 43.0, and 111.0 ng/mL, respectively, and
the functional sensitivity was 0.7 ng/mL. Anti-Tg Ab and
anti-thyroid peroxidase Ab were measured by a
competitive radioimmunoassay (RIA) kit (ZenTech,
Angleur, Belgium), and the given normal range was < 70
IU/mL and 50 IU/mL, respectively. TSH levels were
measured by an IRMA kit (Beckman Coulter, Prague,
Czech Republic), with a detection limit of 0.025 mIU/L.
The intra- and inter-assay CV were 3.7% and 5.7%,
respectively. Follow-up management of patients with DTC
after surgery included physical examination, serum TSH,
free T4, Tg, and anti-Tg Ab measurements with or without
calcium and phosphorus tests. These tests were repeated
at 3-month or shorter intervals and continued for the first
2 years after surgery.
Follow-up management
All patients underwent an initial follow-up examination
with clinical evaluation, 
123I DxWBS, and Tg after L-
thyroxine withdrawal with or without US 6 to 12 months
after RAI. DxWBS results were visually interpreted by two
experienced nuclear medicine physicians who reached a
consensus. Strong radioiodine uptake in the thyroid bed
on initial post-therapeutic whole-body scan (TxWBS) was
interpreted as a normal thyroid remnant.
Stimulated Tg levels above 5 to 10 ng/mL were consi-
dered to indicate residual or recurrent tumor, regardless
of the WBS finding. Stimulated Tg < 1 ng/mL, negative
DxWBS, and normal US, when performed, were
considered as lack of evidence for recurrent/persistent
disease. Anterior neck uptake in the thyroid bed without
abnormal radioiodine uptake elsewhere on WBS, despite410 The Korean Journal of Internal Medicine Vol. 25, No. 4, December 2010
negative Tg levels < 1 ng/mL, was the target. WBS+Tg-
patients were managed according to each physician's
clinical decision and not according to a specific common
treatment protocol. The treatment group who received a
second bout of RAI therapy was followed up with Tg and
DxWBS and/or US within 1 year. The observation group
had Tg measurements and US and/or DxWBS performed
within 6 to 12 months. Other imaging studies such as
computed tomography (CT), magnetic resonance imaging
(MRI), and F-18 fluorodeoxyglucose positron emission
tomography/CT (FDG PET/CT) were performed when
metastasis outside the neck was clinically suspected. This
study was approved by our institutional review board.
Statistical analysis
Statistical analysis of the categorical variables was
conducted using a χ
2 test or Fisher's exact test.
Comparisons between continuous variables were
performed with an independent t test. A p value < 0.05
was considered statistically significant. All the analyses
were performed using SPSS version 12.0 (SPSS Inc.,
Chicago, IL, USA).
RESULTS
Among 389 patients with DTC, 44 (11.3%) showed
thyroid bed uptake on DxWBS but negative thyroglobulin
levels (WBS+Tg-) 6 to 12 months after initial remnant
ablation with high-dose RAI. The success rate of initial
high-dose remnant ablation was 64.8% (252/389), which
was the number of WBS-Tg- subjects. The number of
cases according to the four different combinations of WBS
and serum Tg level results is presented in Fig. 1. There
were no differences in clinical and pathological
parameters between the WBS+Tg- group and the WBS-
Tg- group except for thyroiditis, which was more
frequently observed in WBS+Tg- patients (27.3% vs.
11.5%, p = 0.005) (Table 1). Other clinical and histological
characteristics and factors of prognostic relevance are
summarized in Table 1. Additionally, there was no
significant difference between WBS+Tg- and WBS-Tg-
groups in the time from high-dose remnant ablation to the
first follow-up DxWBS, although there was a trend toward
a slightly longer duration in the WBS-Tg- group
(WBS+Tg- vs. WBS-Tg-, 7.4 ± 2.1 months vs. 8.1 ± 3.7
months, p = 0.073). Of the 44 WBS+Tg- patients, 27 were
treated with repeated high-dose RAI therapy (100 or 150
mCi) in addition to the first RAI (Table 2). The other 17
patients were observed without further RAI. The
treatment group (n = 27) and observation only group (n =
17) were allocated as determined solely by each physicians'
clinical decision without randomization or blinding.
However, the two groups showed no significant
differences in clinical and post-operative pathology risk
parameters (data not shown). 
All treated subjects displayed thyroid bed uptake in
therapeutic WBS after repeat RAI therapy, with the
exception of three patients who showed no definite uptake
either inside or outside the thyroid bed. Of the 27 treated
subjects, 25 showed no uptake in the thyroid bed on the
next DxWBS. The other two patients were checked only by
US, which revealed no evidence of remnant or recurrent
disease (Table 2). Of the 17 patients in the observation
only group, eight showed no uptake in the thyroid bed on
subsequent DxWBS without further treatment. Among
the other nine patients, six patients demonstrated
negative US findings, and follow-up DxWBS was not
performed. Two patients showed persistent uptake on
follow-up DxWBS. One patient showed a small
hypoechoic lesion (3.1 × 3.8 mm) in the thyroid bed, which
was regressed and then eventually resolved on annual US
examination, and the other patient showed negative US
findings (Table 2). One patient was lost to follow-up.
During the 53.2 ± 10.1-month follow-up period, all but
two suspicious cases out of the 44 WBS+Tg- subjects were
Figure 1. Classification of study subjects according to the first
diagnostic whole body scan (WBS) and thyroid stimulating
hormone (TSH)-stimulated serum thyroglobulin (Tg) results 6-
12 months after high-dose radioiodine remnant ablation.
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negative for recurrence. A case from the treated group
showed mildly increased Tg levels (1.16 ng/mL) off L-
thyroxine with no uptake on follow-up DxWBS. Another
treated case showed a < 5-mm-diameter hypoechoic
lesion in the thyroid bed in two consecutive US findings
with no interval change. Both cases were recurrence free if
a Tg level of 2 ng/mL was used as a cut-off, and the US
detected a post-operative granuloma.
Table 2. Comparison between observation group and RAI-treated group in subjects with WBS+Tg- 
WBS+Tg- group (n = 44) Observation group (n = 17) Treatment group (n = 27)
No uptake in F/U DxWBS 8 25
US performed 7 16
Negative 7 15
Hypoehoic lesion 0 1
b
US not performed 1 9
c
Persistent uptake in F/U DxWBS 2
a 0
Negative US without F/U WBS 6 2
Follow-up loss 1 0
RAI, radioiodine therapy; WBS, whole body scan; Tg, thyroglobulin; F/U, follow-up; DxWBS, diagnostic WBS; US,
ultrasonography.
aPatient 1 showed one small hypoehoic lesion sized 3.1 x 3.8 mm in thyroid bed that was regressed and then eventually  
resolved on annual US examination, and patient 2 showed negative US findings.
bThe small hypoehoic lesion less than 5 mm in thyroid bed in which fine needle aspiration was not feasible showed no 
interval change on follow-up US one year later.
cThe patient showed mildly increased Tg level (1.16 ng/mL) off L-thyroxine with no uptake in follow-up DxWBS.
Table 1. Comparison of clinical and histopathological characteristics among WBS+Tg-, WBS-Tg- and WBS+Tg+
differentiated thyroid cancers
WBS+Tg- WBS-Tg- WBS+Tg+
No. 44 (11.2) 252 (64.8) 30 (7.7)
Gender (female/male) 40/4 (90.9/9.1) 219/33 (86.7/13.3) 22/8 (73.3/26.6)
Age, yr 46.5 ± 8.4 (26-61) 47.8 ± 11.4 (21-74) 46.9 ± 14.0 (25-75)
Maximum tumor size, cm 0.9 ± 0.5 (0.2-2.5) 1.0 ± 0.7 (0.2-4.0) 2.0 ± 1.9 (0.3-10.0)
a
Thyroiditis on pathology 12 (27.3) 29 (11.5)
a 5 (16.7)
Multiplicity 13 (29.5) 62 (24.8) 12 (40.0)
Bilaterality 12 (27.3) 48 (19.0) 9 (30.0)
Extrathyroidal extension 7/40
b (17.5) 58/222
b (26.1) 12/27
b (44.4)
a
Lymphatic invasion 5 (11.4) 37/247
b (15.0) 14/29
b (48.3)
a
Lymph node metastasis 7/12
b (36.8) 38/95
b (40.0) 11/14
b (78.6)
a
Values are presented as mean ± SD (minimum - maximum) or number (%).
WBS, whole body scan; Tg, thyroglobulin.
a p < 0.01 vs. WBS+Tg- by χ
2 test or unpaired t test.
b Number of available recordings.412 The Korean Journal of Internal Medicine Vol. 25, No. 4, December 2010
To investigate the possible effects of remnant thyroid
lesions at the time of initial RAI therapy on subsequent
DxWBS thyroid bed uptake 1 year after RAI, we evaluated
Tg levels and the number of patients with Tg > 1 ng/mL
and Tg > 5 ng/mL at the time of RAI therapy in both
WBS+T- and WBS-Tg- groups (Table 3). No significant
differences were noted in Tg levels or in the number of
patients with Tg levels > 1 ng/mL or > 5 ng/mL between
the WBS+Tg- group and the WBS-Tg- group.
DISCUSSION
Owing to the high sensitivity and specificity of US, the
value and role of DxWBS in DTC follow-up has decreased.
Additionally, the use of DxWBS has been discouraged in
the follow-up of low-risk differentiated thyroid carcinoma.
One recent report supported the utility of pre-ablation
radioiodine scan, although this view remains contentious
[8-10]. In addition, the occasional remnant uptake in the
thyroid bed after high-dose remnant ablation is
considered to be a kind of failure of initial remnant
ablation or a non-specific finding [11]. However, no clear
explanation is available for a WBS-positive lesion with
negative Tg.
In the present study, the clinical characteristics of
WBS+Tg- patients were not different from those of WBS-
Tg- patients. Previous reports ignored the clinical
significance of radioiodine uptake in the thyroid bed after
remnant ablation because of low thyroglobulin levels,
which is considered a good prognostic marker [2,11-13].
However, a few recently published reports emphasized the
importance of WBS [6-8]. One report concerning positive
post-therapeutic WBS uptake outside the thyroid bed and
negative thyroglobulin levels suggested metastatic lesions
rather than false-positive image findings [7]. Another
report demonstrated that many patients were positive for
thyroid bed uptake on DxWBS and negative for Tg levels
after high-dose RAI. These patients responded well to
additional high-dose RAI therapy, discouraging the use of
a negative Tg value as an adequate solitary marker for the
presence and treatment of small cervical remnants [6].
The current findings also suggest that thyroid bed
uptake on DxWBS after high-dose RAI could be easily
treated with subsequent additional radioiodine therapy.
However, little evidence supports the view that this
management plan actually improves survival or decreases
recurrence in such low-risk patients with undetectable Tg
levels. Pacini et al. reported persistence of minor uptake in
the thyroid bed in a minority of patients in whom the
previous ablative dose of 
131I was not totally effective. In
nearly one-third of these cases, spontaneous
disappearance of thyroid bed uptake at the follow-up
DxWBS was observed without retreatment with
radioiodine, suggesting no influence on final outcome [2].
In the present study, both the initial clinical parameters
and last follow-up outcomes, including recurrence rates,
were similar between treatment and observation groups
(Tables 1 and 2). These results suggest that uptake in the
thyroid bed concurrent with negative Tg does not require
immediate treatment. When considering reports about
the hazards of RAI therapy in DTC patients, such as
second primary malignancy [14-16] and chronic
sialadenitis [17,18], additional high-dose RAI therapy
aimed at decreasing remnant uptake in WBS may do
more harm than good. Moreover, the difficulties the
patient endures during radioiodine therapy, including the
tedious low-iodine diet, long period of hypothyroidism,
and acute radiation-induced side effects, must also be
taken into consideration. Moreover, as US can detect
suspicious lesions of very small volume in the neck area, it
would be reasonable to use US for monitoring low-risk
Table 3. Comparison of thyroglobulin (Tg) levels between WBS+Tg- and WBS-Tg- groups.
WBS+Tg- (n = 44) WBS-Tg- (n = 252) p value
Thyroglobulin at the time of initial RAI 
Tg levels, ng/mL 0.66 (0.10 - 15.43) 1.33 (0.02 - 25.56) 0.494
No. of patients with Tg > 1 ng/mL 18 (40.9) 134/251
a (53.4) 0.126
No. of patients with Tg > 5 ng/nL 5 (11.4) 44/251
a (17.5) 0.311
Values are presented as median (minimum - maximum) or number (%).
WBS, whole body scan; RAI, radioiodine therapy.
aNumber of available recordings.Lim DJ, et al. Scan positive, thyroglobulin negative thyroid cancer  413
DTC patients showing WBS uptake only in the thyroid
bed. This policy is already reflected in recent management
guidelines [4,5].
The cause of uptake in the thyroid bed on 
123I DxWBS
following total thyroidectomy and high-dose RAI is
unknown. It is generally believed that the remaining
normal thyroid tissue persists despite high-dose RAI
therapy and that the previous radioiodine dose is not
totally effective in these patients [2]. On the other hand,
according to some reports, a small tumor mass detected
by WBS might account for negative Tg levels, and after
repeated radioiodine therapy, viable cancer cells diminish
and eventually disappear on WBS [7,19]. The fact that
microscopic thyroiditis was more frequently observed on
WBS+Tg- on post-operative pathology (Table 1) led us to
retrospectively review anti-Tg Ab and anti-TPO Ab status.
Although anti-TPO Ab measurement was not performed
pre- and post-operatively in most of the cases, anti-Tg Ab
is a routine laboratory parameter in our thyroid nodule
clinic along with Tg. Additionally, pre- and post-operative
follow-up measurements were available in the majority of
cases.
Serum anti-Tg Ab levels in WBS+Tg- patients tended to
be higher than that in WBS-Tg- patients within the
normal range (data not shown), suggesting that remaining
autoimmune processes or some sort of mild inflammatory
condition might be involved in thyroid bed uptake on
DxWBS. However, it is not yet fully understood whether
increased serum anti-Tg Ab levels reflect remnant normal
thyroid tissue.
The present study did not detect differences in
thyroglobulin levels immediately at the time of initial
high-dose RAI, which reflects remnant thyroid tissue after
total thyroidectomy. These results indirectly suggest that
the initial volume of remnant thyroid tissue has no effect
on thyroid bed uptake in subsequent DxWBS. However,
as undetectable serum Tg levels always signify no minimal
tumor burden in patients who have already been treated
with RAI [20], US should be used to evaluate metastatic
lymph nodes in such patients.
Another distinguishing feature of this study was the use
of 
123I for diagnostic WBS instead of 
131I for the first and the
second follow-up 6 to 12 months after RAI. It was
reported that 
123I diagnostic WBS is comparable to post-
therapeutic scans performed immediately after high-dose
RAI therapy, with a concordance rate exceeding 95%
[21,22]. The presently observed thyroid bed uptake on 
123I
DxWBS was comparable to the post-therapeutic WBS,
bolstering confidence in assessing the risk stratification of
DTC patients using 
123I DxWBS.
The present study has several limitations. First, the
study was retrospective, and the patients who received
additional RAI therapy were not randomly allocated, but
instead distributed according to each clinician's judgment.
The physician may have decided to repeat radioiodine
therapy in higher-risk patients, even though the clinical
characteristics were not significantly different. Second, the
mean follow-up duration was 53 months, which is too
short to fully evaluate recurrence in the low-risk DTC
group. Finally, although experienced nuclear medicine
physicians reviewed the WBS, the percentage uptake of
radioiodine in the thyroid bed was not routinely
measured, and this may have decreased the accuracy of
WBS.
The results support a wait-and-watch approach without
further high-dose radioiodine treatment as a feasible
option for WBS+Tg- patients, especially those that are low
risk. The present findings should prove useful for thyroid
cancer clinics still performing a DxWBS-based radioactive
iodine therapy. However, a randomized trial with a
greater number of patients is necessary to determine the
long-term significance of WBS thyroid bed uptake despite
low thyroglobulin levels in DTC management.
Conflict of interest
No potential conflict of interest relevant to this article
was reported.
REFERENCES
1. Schlumberger M, Berg G, Cohen O, et al. Follow-up of low-risk
patients with differentiated thyroid carcinoma: a European
perspective. Eur J Endocrinol 2004;150:105-112.
2. Pacini F, Capezzone M, Elisei R, Ceccarelli C, Taddei D, Pinchera
A. Diagnostic 131-iodine whole-body scan may be avoided in
thyroid cancer patients who have undetectable stimulated serum
Tg levels after initial treatment. J Clin Endocrinol Metab
2002;87:1499-1501.
3. Torlontano M, Attard M, Crocetti U, et al. Follow-up of low risk
patients with papillary thyroid cancer: role of neck
ultrasonography in detecting lymph node metastases. J Clin
Endocrinol Metab 2004;89:3402-3407.414 The Korean Journal of Internal Medicine Vol. 25, No. 4, December 2010
4. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga
W. European consensus for the management of patients with
differentiated thyroid carcinoma of the follicular epithelium. Eur
J Endocrinol 2006;154:787-803.
5. American Thyroid Association (ATA) Guidelines Taskforce on
Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS,
Doherty GM, et al. Revised American Thyroid Association
management guidelines for patients with thyroid nodules and
differentiated thyroid cancer. Thyroid 2009;19:1167-1214.
6. Caballero-Calabuig E, Cano-Terol C, Sopena-Monforte R, et al.
Influence of the thyroid remnant in the elevation of the serum
thyroglobulin after thyroidectomy in differentiated thyroid
carcinoma. Importance of the diagnostic iodine total-body
scanning. Eur J Nucl Med Mol Imaging 2008;35:1449-1456.
7. Park EK, Chung JK, Lim IH, et al. Recurrent/metastatic thyroid
carcinomas false negative for serum thyroglobulin but positive by
posttherapy I-131 whole body scans. Eur J Nucl Med Mol Imaging
2009;36:172-179.
8.Van Nostrand D, Aiken M, Atkins F, et al. The utility of
radioiodine scans prior to iodine 131 ablation in patients with
well-differentiated thyroid cancer. Thyroid 2009;19:849-855.
9. Schlumberger MJ, Pacini F. The low utility of pretherapy scans in
thyroid cancer patients. Thyroid 2009;19:815-816.
10.McDougall IR. The case for obtaining a diagnostic whole-body
scan prior to iodine 131 treatment of differentiated thyroid cancer.
Thyroid 2009;19:811-813.
11. Cailleux AF, Baudin E, Travagli JP, Ricard M, Schlumberger M. Is
diagnostic iodine-131 scanning useful after total thyroid ablation
for differentiated thyroid cancer? J Clin Endocrinol Metab
2000;85:175-178.
12. Baudin E, Do Cao C, Cailleux AF, Leboulleux S, Travagli JP,
Schlumberger M. Positive predictive value of serum thyroglobulin
levels, measured during the first year of follow-up after thyroid
hormone withdrawal, in thyroid cancer patients. J Clin
Endocrinol Metab 2003;88:1107-1111.
13. Mazzaferri EL, Robbins RJ, Spencer CA, et al. A consensus report
of the role of serum thyroglobulin as a monitoring method for
low-risk patients with papillary thyroid carcinoma. J Clin
Endocrinol Metab 2003;88:1433-1441.
14. Brown AP, Chen J, Hitchcock YJ, Szabo A, Shrieve DC, Tward JD.
The risk of second primary malignancies up to three decades after
the treatment of differentiated thyroid cancer. J Clin Endocrinol
Metab 2008;93:504-515.
15. Rubino C, de Vathaire F, Dottorini ME, et al. Second primary
malignancies in thyroid cancer patients. Br J Cancer
2003;89:1638-1644.
16. Ronckers CM, McCarron P, Ron E. Thyroid cancer and multiple
primary tumors in the SEER cancer registries. Int J Cancer
2005;117:281-288.
17. Hyer S, Kong A, Pratt B, Harmer C. Salivary gland toxicity after
radioiodine therapy for thyroid cancer. Clin Oncol (R Coll Radiol)
2007;19:83-86.
18.Alexander C, Bader JB, Schaefer A, Finke C, Kirsch CM.
Intermediate and long-term side effects of high-dose radioiodine
therapy for thyroid carcinoma. J Nucl Med 1998;39:1551-1554.
19. Müller-Gärtner HW, Schneider C. Clinical evaluation of tumor
characteristics predisposing serum thyroglobulin to be
undetectable in patients with differentiated thyroid cancer.
Cancer 1988;61:976-981.
20.Bachelot A, Cailleux AF, Klain M, et al. Relationship between
tumor burden and serum thyroglobulin level in patients with
papillary and follicular thyroid carcinoma. Thyroid 2002;12:707-
711.
21. Urhan M, Dadparvar S, Mavi A, et al. Iodine-123 as a diagnostic
imaging agent in differentiated thyroid carcinoma: a comparison
with iodine-131 post-treatment scanning and serum thyroglobulin
measurement. Eur J Nucl Med Mol Imaging 2007;34:1012-1017.
22.Alzahrani AS, Bakheet S, Al Mandil M, Al-Hajjaj A, Almahfouz A,
Al Haj A. 123I isotope as a diagnostic agent in the follow-up of
patients with differentiated thyroid cancer: comparison with post
131I therapy whole body scanning. J Clin Endocrinol Metab
2001;86:5294-5300.